Prescription and over-the-counter medicine
Bacitracin, hydrocortisone, neomycin and polymyxin b First approved as Cortisporin
Bacitracin, hydrocortisone, neomycin and polymyxin b (Cortisporin) is a prescription and over-the-counter medicine with an FDA approval on record since 1957. FDA's NDC Directory lists it from 1 generic labeler, and pharmacies paid $5.52 per gram (Neo-bacit-poly-hc eye ointment) in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the bacitracin, hydrocortisone, neomycin and polymyxin b FDA label on DailyMed (effective January 2, 2025, Bausch & Lomb Incorporated); the NDA 50168 record on Drugs@FDA; every bacitracin, hydrocortisone, neomycin and polymyxin b label on DailyMed.
Highlights of the record
FDA label of January 2, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageNeomycin and polymyxin B sulfates, bacitracin zinc and hydrocortisone ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists.
Forms and strengths
- 3.5 mg/g / 10 mg/g
Ointment.
On the market
- Earliest approval on file
- March 26, 1957 Cortisporin, Monarch Pharms; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 3 first April 14, 1981; 1 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 1 of which 1 under generic applications, 0 under brand applications, repackagers included; 1 more under the over-the-counter monograph, without an application
Supply and safety
- Pharmacy cost (NADAC)
- $5.52 per gram Neo-bacit-poly-hc eye ointment
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 7 through July 30, 2026
What is bacitracin, hydrocortisone, neomycin and polymyxin b used for?
From the label: indications and usageNeomycin and polymyxin B sulfates, bacitracin zinc and hydrocortisone ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. […]
Conditions named in the indications of bacitracin, hydrocortisone, neomycin and polymyxin b's FDA labels, with every medicine labeled for each:
From other bacitracin, hydrocortisone, neomycin and polymyxin b labelsBacterial infections: … inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists.
FDA pharmacologic class: Aminoglycoside Antibacterial, Corticosteroid and Polymyxin-class Antibacterial.
Source: FDA drug label (Neomycin and Polymyxin B Sulfates, Bacitracin Zinc and Hydrocortisone), Bausch & Lomb Incorporated, effective January 2, 2025 (SPL set 3b00eb5c-dd98-467e-a883-04c37a8ecc42), via openFDA; the full label on DailyMed
Is there a generic for bacitracin, hydrocortisone, neomycin and polymyxin b (Cortisporin)?
The FDA approved the first generic bacitracin, hydrocortisone, neomycin and polymyxin b on April 14, 1981. 3 generic applications are approved; 1 of them carries a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists bacitracin, hydrocortisone, neomycin and polymyxin b from 1 labeler under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1957 earliest approval on file
- 1981 first generic approved
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for bacitracin, hydrocortisone, neomycin and polymyxin b (Cortisporin)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $5.52 per gram (Neo-bacit-poly-hc eye ointment), down 9% from $6.07 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Neo-bacit-poly-hc eye ointment (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Neo-bacit-poly-hc eye ointment | Generic | $5.52 per gram | n/a | -9% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for bacitracin, hydrocortisone, neomycin and polymyxin b?
The FDA Adverse Event Reporting System holds 7 reports that list bacitracin, hydrocortisone, neomycin and polymyxin b among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 3 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as bacitracin, hydrocortisone, neomycin and polymyxin b?
5 other medicines are given the same way (ophthalmic) and in the same FDA class as bacitracin, hydrocortisone, neomycin and polymyxin b or labeled mainly for the same use (bacterial infections), the same class first. Bacterial infections lists all 51 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (ophthalmic) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Tobramycin | Bacterial infections | 18 labelers | $1.11 per mL 0.3% eye drop | A presentation being discontinued |
| Gentamicin | Bacterial infections | 10 labelers | $0.790 per mL 0.3% eye drop | No current entry |
| Ofloxacin | Bacterial infections | 23 labelers | $1.24 per mL 0.3% eye drops | No current entry |
| Sulfacetamide | Bacterial infections | 6 labelers | $1.96 per mL 10% eye drops | No current entry |
| Azithromycin | Bacterial infections | none listed | $98.51 per mL 1% eye drops | A presentation being discontinued |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to bacitracin, hydrocortisone, neomycin and polymyxin b
- 5 medicines for the same use
- Other aminoglycoside antibacterials
- the pharmacologic class, with prices and generics
- Bacitracin, hydrocortisone, neomycin and polymyxin b side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other